Timo L M Ten Hagen Selected Research

Timo L M Ten Hagen Research Topics

Disease

57	Neoplasms (Cancer) 11/2023 - 11/2002
16	Melanoma (Melanoma, Malignant) 04/2021 - 07/2003
10	Hyperthermia 10/2023 - 06/2011
7	Breast Neoplasms (Breast Cancer) 12/2022 - 05/2010
5	Neoplasm Metastasis (Metastasis) 01/2023 - 08/2011
5	Sarcoma (Soft Tissue Sarcoma) 08/2020 - 07/2005
4	Colorectal Neoplasms (Colorectal Cancer) 11/2016 - 04/2015
2	Carcinogenesis 01/2023 - 11/2012
2	Squamous Cell Carcinoma of Head and Neck 01/2020 - 01/2016
2	Head and Neck Neoplasms (Head and Neck Cancer) 01/2020 - 01/2013
2	Necrosis 04/2006 - 11/2002
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 10/2023
1	Thyroid Neoplasms (Thyroid Cancer) 02/2022
1	Eye Diseases (Eye Disease) 03/2020
1	Uterine Cervical Dysplasia 01/2016
1	Basal Cell Carcinoma (Rodent Ulcer) 01/2016

Drug/Important Bio-Agent (IBA)

21	Liposomes (Liposome)IBA 10/2022 - 11/2002
9	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2021 - 11/2013
7	LipidsIBA 10/2022 - 08/2015
5	Proteins (Proteins, Gene)FDA Link 01/2023 - 05/2010
5	Peptides (Polypeptides)IBA 02/2022 - 05/2014
5	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/2022 - 01/2014
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2014 - 11/2002
4	AntigensIBA 04/2023 - 01/2016
4	SphingolipidsIBA 08/2020 - 04/2015
4	AntibodiesIBA 01/2020 - 05/2010
3	Therapeutic UsesIBA 01/2020 - 03/2016
3	ErbB Receptors (EGF Receptor)IBA 01/2020 - 07/2015
3	Cetuximab (Erbitux)FDA Link 01/2020 - 07/2015
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2019 - 02/2012
3	Phosphoric Monoester Hydrolases (Phosphatases)IBA 11/2016 - 04/2015
3	liposomal doxorubicin (Doxil)FDA Link 03/2016 - 11/2013
2	LigandsIBA 02/2022 - 10/2016
2	Photosensitizing Agents (Photosensitizers)IBA 01/2022 - 01/2020
2	AnthracyclinesIBA 01/2021 - 08/2015
2	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 01/2021 - 12/2015
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2019 - 01/2016
2	Single-Chain AntibodiesIBA 01/2019 - 01/2016
2	Phosphotransferases (Kinase)IBA 11/2016 - 04/2016
2	Tissue Inhibitor of Metalloproteinase-3IBA 10/2016 - 01/2014
2	Immunoglobulin Fab FragmentsIBA 10/2016 - 07/2015
2	Conditioned Culture MediaIBA 01/2016 - 01/2014
2	IntegrinsIBA 12/2015 - 06/2013
2	Mitoxantrone (Novantrone)FDA LinkGeneric 08/2015 - 04/2015
2	Somatostatin Receptors (Somatostatin Receptor)IBA 05/2014 - 01/2014
2	Octreotide (Sandostatin)FDA LinkGeneric 05/2014 - 01/2014
2	Melphalan (Alkeran)FDA LinkGeneric 06/2013 - 07/2005
2	Interleukin-2 (IL2)IBA 02/2012 - 03/2011
1	GadoliniumIBA 11/2023
1	Metal-Organic FrameworksIBA 11/2023
1	GoldIBA 11/2023
1	DNA (Deoxyribonucleic Acid)IBA 10/2023
1	Transferrin (beta 2 Transferrin)IBA 06/2023
1	Epidermal Growth Factor (EGF)IBA 04/2023
1	Neoplasm Antigens (Tumor Antigens)IBA 04/2023
1	CarbohydratesIBA 04/2023
1	Carcinoembryonic AntigenIBA 04/2023
1	Tumor Biomarkers (Tumor Markers)IBA 04/2023
1	Prostate-Specific Antigen (Semenogelase)IBA 04/2023
1	Keratin-19 (Keratin 19)IBA 04/2023
1	MicroRNAs (MicroRNA)IBA 01/2023
1	Circular RNAIBA 01/2023
1	CateninsIBA 01/2023
1	Sirolimus (Rapamycin)FDA Link 12/2022
1	PolymersIBA 10/2022
1	SuspensionsIBA 08/2022
1	Hormones (Hormone)IBA 08/2022
1	piperineIBA 08/2022
1	aspartic acid glycine arginineIBA 02/2022
1	Cell-Penetrating PeptidesIBA 02/2022
1	Trans-Activators (Trans-Acting Factor)IBA 02/2022
1	Competitive Endogenous RNAIBA 02/2022
1	Single-Domain AntibodiesIBA 01/2022
1	Protein CoronaIBA 01/2022
1	Coloring Agents (Dyes)IBA 01/2021
1	SDDSIBA 01/2021
1	phthalocyanineIBA 01/2020
1	EpitopesIBA 01/2020
1	Chimeric Antigen ReceptorsIBA 01/2020
1	Caspase 3 (Caspase-3)IBA 01/2020
1	HLA-A2 Antigen (HLA A2 Antigen)IBA 01/2020
1	Oncogene Proteins (Oncogene Protein)IBA 12/2019
1	rhoA GTP-Binding ProteinIBA 12/2019
1	Dihydrotachysterol (AT 10)IBA 01/2019
1	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 11/2016
1	phosphoinositide-3,4-bisphosphateIBA 11/2016
1	Contrast MediaIBA 01/2016
1	Drug CarriersIBA 01/2016
1	p38 Mitogen-Activated Protein KinasesIBA 01/2016

Therapy/Procedure

19	Therapeutics 11/2023 - 08/2011
9	Drug Therapy (Chemotherapy) 08/2022 - 10/2007
4	Immunotherapy 12/2021 - 07/2003
4	Induced Hyperthermia (Thermotherapy) 01/2021 - 01/2016
3	Radiotherapy 10/2023 - 11/2002
3	Photochemotherapy (Photodynamic Therapy) 01/2022 - 01/2020
3	Lasers (Laser) 01/2020 - 11/2002
2	Injections 10/2021 - 10/2007
1	Precision Medicine 11/2023
1	Quantum Dots (Quantum Dot) 11/2023
1	Communication Aids for Disabled (TDD) 01/2022